Cite this article
Volume | Year
European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.
The association between polymorphisms of the RAD51- G135C, XRCC2-Arg188His and XRCC3-Thr241Met genes and clinico-pathologic features in breast cancer in Poland
H. Romanowicz-Makowska1,*, B. Smolarz1, M. Zadrożny Zadrożny2, B. Westfal2, J. Baszczyński Baszczyński2, G. Kokołaszwili Kokołaszwili3, M. Burzyński Burzyński3, I. Połać Połać4, S. Sporny5
1 Laboratory of Molecular Genetics, Department of Pathology, Institute of Polish Mother’s Memorial Hospital, Lodz
2 Department of Oncology, Institute of Polish Mother’s Memorial Hospital, Lodz
3 Department of Obstetrics and Gynecology, Regional Hospital in Lowicz
4 Department of Menopausal Diseases, Institute of Polish Mother’s Memorial Hospital, Lodz
5 Department of Pathology, Medical University of Lodz (Poland)
Eur. J. Gynaecol. Oncol. 2012, 33(2), 145–150;
Published: 10 April 2012
Background: XRCC2 and XRCC3 genes are structurally and functionally related to RAD51 which plays an important role in homologous recombination, the process frequently involved in cancer transformation. Material and Methods: In the present work the distribution of genotypes and frequency of alleles of the RAD51 G135C polymorphism, XRCC2 Arg188His and XRCC3 Thr241Met polymorphism in 790 cases of breast cancer were investigated. The control group consisted of 798 cancer-free blood donors (age ± 5 years) who were sex and ethnicity-matched. The polymorphisms were determined by PCR-RFLP methods. We also correlated genotypes with the clinical characteristics of breast cancer patients. Results: Our results obtained for the 135G>C polymorphism of the RAD51 gene indicated that both the C/C genotype and the C allele are strongly associated with breast cancer. The Arg/His genotype of XRCC2 (OR = 2.16, 95% CI = 1.48-3.16) and Thr/Met of XRCC3 increased the risk of type I breast cancer occurrence (OR = 2.33,95% CI = 1.60-3.41). We did not find any association with the RAD51, XRCC2/3 gene polymorphism and estrogen and progesterone receptor status. Conclusion: The results support the hypothesis that the polymorphism of RAD51 and XRCC2/3 gene may be associated with the incidence of sporadic breast cancer in Polish women.